ЛІПОСОМИ ДЛЯ ОРАЛЬНОЇ ДОСТАВКИ ПРЕПАРАТІВ: ПЕРСПЕКТИВИ ТА ОБМЕЖЕННЯ

Abstract

Оральний шлях введення є найбільш зручним і широко застосовуваним у клінічній практиці, однак він пов'язаний із суттєвими бар'єрами для біодоступності багатьох лікарських речовин. Ліпосомальна інкапсуляція розглядається як перспективна стратегія подолання цих бар'єрів за рахунок захисту АФІ від деградації в шлунково-кишковому тракті, підвищення проникності через кишковий епітелій і модуляції фармакокінетичного профілю. У цьому огляді розглянуто механізми орального всмоктування ліпосом, ключові бар'єри шлунково-кишкового тракту, сучасні підходи до підвищення стабільності та біодоступності, а також наведено приклади клінічного застосування ліпосомальних оральних форм.

References

1. Homayun B., Lin X., Choi H.-J. Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals // Pharmaceutics. – 2019. – Vol. 11, № 3. – P. 129.
2. Amidon G.L., Lennernäs H., Shah V.P., Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability // Pharmaceutical Research. – 1995. – Vol. 12, № 3. – P. 413–420.
3. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers // Nature Reviews Drug Discovery. – 2005. – Vol. 4, № 2. – P. 145–160.
4. Lian T., Ho R.J.Y. Trends and developments in liposome drug delivery systems // Journal of Pharmaceutical Sciences. – 2001. – Vol. 90, № 6. – P. 667–680.
5. Storch J., Kleinfeld A.M. Transfer of long-chain fluorescent free fatty acids between unilamellar vesicles // Biochemistry. – 1986. – Vol. 25, № 7. – P. 1717–1726.
6. Dressman J.B., Amidon G.L., Reppas C., Shah V.P. Dissolution testing as a prognostic tool for oral drug absorption // Pharmaceutical Research. – 1998. – Vol. 15, № 1. – P. 11–22.
7. Bezzine S., Koduri R.S., Valentin E. et al. Exogenously added human group X secreted phospholipase A2 but not the group IB, IIA, and V enzymes efficiently release arachidonic acid from adherent mammalian cells // Journal of Biological Chemistry. – 2000. – Vol. 275, № 5. – P. 3179–3191.
8. Carey M.C., Small D.M., Bliss C.M. Lipid digestion and absorption // Annual Review of Physiology. – 1983. – Vol. 45. – P. 651–677.
9. Crater J.S., Carrier R.L. Barrier properties of gastrointestinal mucus to nanoparticle transport // Macromolecular Bioscience. – 2010. – Vol. 10, № 12. – P. 1473–1483.
10. Pelaseyed T., Bergström J.H., Gustafsson J.K. et al. The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system // Immunological Reviews. – 2014. – Vol. 260, № 1. – P. 8–20.
11. Ulluwishewa D., Anderson R.C., McNabb W.C. et al. Regulation of tight junction permeability by intestinal bacteria and dietary components // Journal of Nutrition. – 2011. – Vol. 141, № 5. – P. 769–776.
12. Kernéis S., Bogdanova A., Kraehenbuhl J.P., Pringault E. Conversion by Peyer's patch lymphocytes of human enterocytes into M cells that transport bacteria // Science. – 1997. – Vol. 277, № 5328. – P. 949–952.
13. Kobayashi T., Startchev K., Whitney A.J., Gruenberg J. Localization of lysobisphosphatidic acid-rich membrane domains in late endosomes // Biological Chemistry. – 2001. – Vol. 382, № 3. – P. 483–485.
14. Papahadjopoulos D., Vail W.J., Jacobson K., Poste G. Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles // Biochimica et Biophysica Acta. – 1975. – Vol. 394, № 3. – P. 483–491.
15. Trevaskis N.L., Charman W.N., Porter C.J.H. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update // Advanced Drug Delivery Reviews. – 2008. – Vol. 60, № 6. – P. 702–716.
16. Immordino M.L., Dosio F., Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential // International Journal of Nanomedicine. – 2006. – Vol. 1, № 3. – P. 297–315.
17. Romberg B., Hennink W.E., Storm G. Sheddable coatings for long-circulating nanoparticles // Pharmaceutical Research. – 2008. – Vol. 25, № 1. – P. 55–71.
18. Plapied L., Duhem N., des Rieux A., Préat V. Fate of polymeric nanocarriers for oral drug delivery // Current Opinion in Colloid and Interface Science. – 2011. – Vol. 16, № 3. – P. 228–237.
19. Vijayanathan V., Thomas T., Thomas T.J. DNA nanoparticles and development of DNA delivery vehicles for gene therapy // Biochemistry. – 2002. – Vol. 41, № 48. – P. 14085–14094.
20. Zhang Y., Bhavna S., Panyam J. Nanoparticles in drug delivery: the case of lipid-polymer hybrid particles // Nanomedicine. – 2012. – Vol. 7, № 9. – P. 1351–1356.
21. Crommelin D.J.A., Fransen G., Hennink W.E. Stability and degradation of liposomes in biological environments // Topics in Pharmaceutical Sciences / Ed. D.D. Breimer, P. Speiser. – Amsterdam: Elsevier, 1987. – P. 267–286.
22. Liang X., Mao G., Ng K.Y.S. Effect of chain lengths of PEO-PPO-PEO on small unilamellar liposome morphology and stability // Journal of Colloid and Interface Science. – 2005. – Vol. 285, № 1. – P. 360–372.
23. Bhardwaj U., Burgess D.J. Physicochemical properties of extruded and non-extruded liposomes containing the hydrophobic drug dexamethasone // International Journal of Pharmaceutics. – 2010. – Vol. 388, № 1–2. – P. 181–189.
24. Lehr C.M., Bouwstra J.A., Schacht E.H., Junginger H.E. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers // International Journal of Pharmaceutics. – 1992. – Vol. 78, № 1–3. – P. 43–48.
25. Des Rieux A., Fievez V., Garinot M., Schneider Y.-J., Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach // Journal of Controlled Release. – 2006. – Vol. 116, № 1. –
26. P. 1–27.
27. Zhang M., Xu C., Liu D., Han M.K., Wang L., Merlin D. Oral delivery of nanoparticles loaded with ginger active compound, 6-shogaol, attenuates ulcerative colitis and promotes wound healing in a murine model // Journal of Crohn's and Colitis. – 2018. – Vol. 12, № 2. – P. 217–229.
28. Sinha V.R., Kumria R. Polysaccharides in colon-specific drug delivery // International Journal of Pharmaceutics. – 2001. – Vol. 224, № 1–2. – P. 19–38.
29. Hanning S.M., Rahme K. The effect of the gut microbiome on nanoparticle drug delivery: a pharmacodynamic review // Journal of Drug Delivery Science and Technology. – 2020. – Vol. 57. – P. 101717.
30. Woitiski C.B., Sarmento B., Carvalho R.A., Neufeld R.J., Veiga F. Facilitated nanoscale delivery of insulin across intestinal membrane models // International Journal of Pharmaceutics. – 2011. – Vol. 412, № 1–2. – P. 123–131.
31. Mueller E.A., Kovarik J.M., van Bree J.B., Grevel J., Lücker P.W., Kutz K. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation // Pharmaceutical Research. – 1994. – Vol. 11, № 2. – P. 301–304.
32. Zhang S., Zhao B., Jiang H., Wang B., Ma B. Cationic lipids and polymers mediated vectors for delivery of siRNA // Journal of Controlled Release. – 2007. – Vol. 123, № 1. – P. 1–10.
33. Akbarzadeh A., Rezaei-Sadabady R., Davaran S. et al. Liposome: classification, preparation, and applications // Nanoscale Research Letters. – 2013. – Vol. 8, № 1. – P. 102.
34. Carr A.C., Vissers M.C.M., Cook J.S. The effect of intravenous vitamin C on cancer- and chemotherapy-related fatigue and quality of life // Frontiers in Oncology. – 2014. – Vol. 4. – P. 283.
35. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings // Advanced Drug Delivery Reviews. – 2001. – Vol. 46, № 1–3. – P. 3–26.
36. Laouini A., Jaafar-Maalej C., Limayem-Blouza I., Sfar S., Charcosset C., Fessi H. Preparation, characterization and applications of liposomes: state of the art // Journal of Colloid Science and Biotechnology. – 2012. – Vol. 1, № 2. – P. 147–168.
37. FDA Draft Guidance for Industry: Liposome Drug Products. Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation. – Silver Spring: FDA, 2018. – Р. 41.